Ignite Creation Date:
2024-05-06 @ 8:31 AM
Last Modification Date:
2024-10-26 @ 12:01 PM
Study NCT ID:
NCT02751138
Status:
COMPLETED
Last Update Posted:
2023-05-16
First Post:
2016-04-19
Brief Title:
Determination of Immune Phenotype in Glioblastoma Patients
Sponsor:
University of Ulm
Organization:
University of Ulm
Study Overview
Official Title:
Determination of Immune Phenotype in Glioblastoma Patients
Status:
COMPLETED
Status Verified Date:
2023-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Glioblastoma multiforme GBM is the most common primary brain tumor in adults Despite intensive research efforts and a multimodal management that actually consists of surgery radiotherapy and chemotherapy with temozolomide the prognosis is dismal The aim of the current observational study is to determine immune phenotypes in individual patients with GBM at the time of diagnosis and to correlate tumor size location imaging tumor properties isocitrate dehydrogenase - 1 IDH-1 o6-methylguanine-DNA-methyltransferase MGMT epidermal growth factor receptor EGFR mutation status etc with clinical data such as progression free and overall survival Karnofsky index progression free survival PFSoverall survival OS Karnofsky score KFS with blood immune phenotypes biomarkers and immune histochemical results of tumor infiltrating lymphocytes macrophages myeloid derived suppressor cells MDSC etc The different immunological phenotypes could predict a positive response to specific immunological therapeutic strategies and select the individual therapeutic plan for an individual GBM patient
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None